US FDA Testing ‘Discount’ Multivitamins 'Very Soon’
Executive Summary
“Over the last year or so, we've had some concerns about the quality of some of the discount multivitamins that are on the market,” says Michael Dutcher, director of the ORA Office of Human and Animal Food Operations' Minneapolis region.
You may also be interested in...
Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort
Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.
Basic Supplement GMP Compliance Problems Continue In FDA Warnings
The agency posts warning letters sent Jan. 23 to Herbal Science International Inc. in City of Industry, Calif. and Jan. 31 to Berkeley Nutritional Manufacturing Corp. in Livermore, Calif.
Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.